Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the spine and sacroiliac joints. Mediators such as macrophage migration inhibitory factor (MIF) and interleukin-10 (IL-10) are thought to be involved in several inflammatory conditions, including AS. Proinflammatory cytokines regulate the production of oxidative stress markers, such as nitric oxide (NO) and malondialdehyde (MDA). Although oxidative stress and lipid peroxidation have been reported in AS, the association of AS with commonly known oxidative stress markers and cytokines remains uncertain. We have therefore studied whether serum MIF levels are elevated in patients with AS and whether the levels correlate with oxidative stress markers and disease activity parameters. Twenty-five AS patients and 18 healthy controls participated in this study; subjects with hypertension, diabetes, hyperlipidemia, and obesity were excluded. The levels of acute phase reactants, serum levels of glucose, lipids, MIF, IL-10, NO and MDA were studied. Spinal mobility was assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI). Patients were also assessed using with the Bath Ankylosing Spondylitis Functional Index and the Bath Ankylosing Spondylitis Disease Activity Index. Age and sex distribution were found to be comparable between AS patients and controls (p > 0.05). Acute phase reactants and MIF levels were significantly higher (p < 0.05) and IL-10 levels were significantly lower (<0.001) in the AS patients than in controls. There was a significant correlation between BASMI and MIF levels in AS patients (r = 0.714, p < 0.001). Based on these results, MIF may be involved in the pathogenesis of the chronic inflammation in AS and, consequently, targeting MIF may be beneficial in preventing complications or in initiating early treatment of the disease.
- van der Linden S, van der Heijde D. Ankylosing spondylitis. Clinical features. Rheum Dis Clin North Am. 1998;24:663–76.
- Khan MA, Ball EJ. Genetic aspects of ankylosing spondylitis. Best Pract Res Clin Rheumatol. 2002;16:675–90.
- Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum. 1999;42:2039–44. CrossRef
- Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3:791–800. CrossRef
- Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK 3rd, Santos LL, et al. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther. 2006;8:R132. CrossRef
- Martinez A, Orozco G, Varade J, Sanchez Lopez M, Pascual D, Balsa A, et al. Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol. 2007;68:744–7. CrossRef
- Willeke P, Gaubitz M, Schotte H, Maaser C, Domschke W, Schluter B, et al. Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjogren’s syndrome. Arthritis Res Ther. 2007;9:R43. CrossRef
- Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol. 2004;31:268–73.
- Zou YQ, Lu LJ, Li SJ, Zeng T, Wang XD, Bao CD, et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still’s disease. Clin Biochem. 2008;41:519–24. CrossRef
- Antoniv TT, Ivashkiv LB. Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 2006;54:2711–21. CrossRef
- Wu J, Cunha FQ, Liew FY, Weiser WY. IL-10 inhibits the synthesis of migration inhibitory factor and migration inhibitory factor-mediated macrophage activation. J Immunol. 1993;151:4325–32.
- Karakoc M, Altindag O, Keles H, Soran N, Selek S. Serum oxidative-antioxidative status in patients with ankylosing spondylitis. Rheumatol Int. 2007;27:1131–4. CrossRef
- Ozgocmen S, Sogut S, Ardicoglu O, Fadillioglu E, Pekkutucu I, Akyol O. Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis. Rheumatol Int. 2004;24:80–3. CrossRef
- Yazici C, Kose K, Calis M, Kuzuguden S, Kirnap M. Protein oxidation status in patients with ankylosing spondylitis. Rheumatology (Oxford). 2004;43:1235–9. CrossRef
- Horton JW. Free radicals and lipid peroxidation mediated injury in burn trauma: the role of antioxidant therapy. Toxicology. 2003;189:75–88. CrossRef
- LeGrand A, Fermor B, Fink C, Pisetsky DS, Weinberg JB, Vail TP, et al. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001;44:2078–83. CrossRef
- Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L, et al. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol. 2008;215:665–75. CrossRef
- Jang D, Murrell GA. Nitric oxide in arthritis. Free Radic Biol Med. 1998;24:1511–9. CrossRef
- Roberts S, Butler RC. Inflammatory mediators as potential therapeutic targets in the spine. Curr Drug Targets Inflamm Allergy. 2005;4:257–66. CrossRef
- Pham TN, Rahman P, Tobin YM, Khraishi MM, Hamilton SF, Alderdice C, et al. Elevated serum nitric oxide levels in patients with inflammatory arthritis associated with co-expression of inducible nitric oxide synthase and protein kinase C-eta in peripheral blood monocyte-derived macrophages. J Rheumatol. 2003;30:2529–34.
- Yang PT, Kasai H, Zhao LJ, Xiao WG, Tanabe F, Ito M. Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol. 2004;138:342–7. CrossRef
- van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8. CrossRef
- Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am J Obstet Gynecol. 1979;135:372–6.
- Navarro-Gonzalvez JA, Garcia-Benayas C, Arenas J. Semiautomated measurement of nitrate in biological fluids. Clin Chem. 1998;44:679–81.
- Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21:1694–8.
- Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.
- Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286–91.
- Stojanovic I, Cvjeticanin T, Lazaroski S, Stosic-Grujicic S, Miljkovic D. Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. Immunology. 2009;126:74–83. CrossRef
- Aeberli D, Leech M, Morand EF. Macrophage migration inhibitory factor and glucocorticoid sensitivity. Rheumatology (Oxford). 2006;45:937–43. CrossRef
- Aeberli D, Yang Y, Mansell A, Santos L, Leech M, Morand EF. Endogenous macrophage migration inhibitory factor modulates glucocorticoid sensitivity in macrophages via effects on MAP kinase phosphatase-1 and p38 MAP kinase. FEBS Lett. 2006;580:974–81. CrossRef
- Chou CT, Huo AP, Chang HN, Tsai CY, Chen WS, Wang HP. Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Arch Med Res. 2007;38:190–5. CrossRef
- Goedecke V, Crane AM, Jaakkola E, Kaluza W, Laiho K, Weeks DE, et al. Interleukin 10 polymorphisms in ankylosing spondylitis. Genes Immun. 2003;4:74–6. CrossRef
- Reikeras O, Helle A, Krohn CD, Brox JI. Systemic and local cytokine kinetics in musculoskeletal injury: a prospective study in patients with ankylosing spondylitis. Scand J Clin Lab Invest. 2008;22:1–6.
- Stavitsky AB, Xianli J. In vitro and in vivo regulation by macrophage migration inhibitory factor (MIF) of expression of MHC-II, costimulatory, adhesion, receptor, and cytokine molecules. Cell Immunol. 2002;217:95–104. CrossRef
- Vazquez-Del MM, Garcia-Gonzalez A, Munoz-Valle JF, Garcia-Iglesias T, Martinez-Bonilla G, Bernard-Medina G, et al. Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol. 2002;29:522–6.
- Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005;52:3020–9. CrossRef
- Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J. 2005;35:419–26. CrossRef
- Biasi D, Carletto A, Caramaschi P, Bellavite P, Andrioli G, Caraffi M, et al. Neutrophil functions, spondylarthropathies and HLA-B27: a study of 43 patients. Clin Exp Rheumatol. 1995;13:623–7.
- Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor
Volume 20, Issue 1 , pp 34-39
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Ankylosing spondylitis
- Macrophage migration inhibitory factor (MIF)
- Oxidative stress
- Industry Sectors
- Author Affiliations
- 1. Department of Biochemistry, Faculty of Medicine, Adnan Menderes University, Adnan Menderes Universitesi Bilim ve Teknoloji Araştırma ve Uygulama Merkezi (ADU-BILTEM), 09100, Aydin, Turkey
- 2. Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
- 4. Dokuz Eylul Universitesi Tip Fakultesi, Romatoloji Bilim Dalı, Balcova, 35340, Izmir, Turkey
- 3. Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey